Skip to main content
Erschienen in: Annals of Surgical Oncology 9/2019

30.05.2019 | Gynecologic Oncology

Impact of Radical Hysterectomy Versus Simple Hysterectomy on Survival of Patients with Stage 2 Endometrial Cancer: A Meta-analysis

verfasst von: Ting Liu, MD, Hua Tu, MD, Yongxue Li, MD, Zhimin Liu, MD, Guochen Liu, MD, Haifeng Gu, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

The strategy of radical surgery for stage 2 endometrial cancer (EC) remains controversial. This meta-analysis aimed to investigate the impact of radical hysterectomy (RH) versus simple hysterectomy (SH) on survival of patients with stage 2 EC.

Methods

A systematic review was conducted to identify studies comparing survival between RH and SH in International Federation of Gynecology and Obstetrics (FIGO) stage 2 EC patients by searching several databases to July 2018. Hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival and progression-free survival were pooled using Stata V.12.0.

Results

The study included 10 retrospective cohort studies enrolling 2866 patients. Patients who received RH did not show a significant survival benefit for either overall survival (pooled HR 0.92; 95% CI 0.72–1.16; P = 0.484) or progression-free survival (pooled HR 0.75; 95% CI 0.39–1.42; P = 0.378). The result remained consistent after it was balanced with possible impact from adjuvant radiotherapy (pooled HR 0.85; 95% CI 0.62–1.16; P = 0.300). In earlier studies that staged patients according to FIGO 1988, RH showed a 27% survival benefit (pooled HR 0.73; 95% CI 0.53–1.00; P = 0.050), whereas in newly published studies based on FIGO 2009 staging, it reversely showed increased risk of death (pooled HR 1.24; 95% CI 0.86–1.77; P = 0.245). However, no statistical significance was reached under either staging criterion.

Conclusions

Based on the results of this meta-analysis, RH does not significantly improve survival in stage 2 EC. The choice of RH remains controversial and should be considered carefully in clinical practice. More qualified studies are needed to determine the best treatment strategy for stage 2 EC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Koh WJ, Abu-Rustum NR, Bean S, et al. Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16:170–99. Koh WJ, Abu-Rustum NR, Bean S, et al. Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16:170–99.
2.
Zurück zum Zitat Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012;120(2, Part 1):383–97. Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012;120(2, Part 1):383–97.
3.
Zurück zum Zitat Colombo NCCA, Group EECC. ESMO–ESGO–ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer. 2015;117:559–81. Colombo NCCA, Group EECC. ESMO–ESGO–ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer. 2015;117:559–81.
4.
Zurück zum Zitat Amant F, Mirza MR, Koskas M, Creutzberg CL. Cancer of the corpus uteri. Int J Gynecol Obstet. 2015;131:S96–104.CrossRef Amant F, Mirza MR, Koskas M, Creutzberg CL. Cancer of the corpus uteri. Int J Gynecol Obstet. 2015;131:S96–104.CrossRef
5.
Zurück zum Zitat Piver MS, Rutledge F, Smith JP. Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol. 1974;44:265–72.PubMed Piver MS, Rutledge F, Smith JP. Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol. 1974;44:265–72.PubMed
6.
Zurück zum Zitat Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.CrossRefPubMed Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.CrossRefPubMed
7.
Zurück zum Zitat Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.CrossRefPubMed Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.CrossRefPubMed
9.
Zurück zum Zitat Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.CrossRefPubMed Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.CrossRefPubMed
10.
Zurück zum Zitat Wright JD, Fiorelli J, Kansler AL, et al. Optimizing the management of stage II endometrial cancer: the role of radical hysterectomy and radiation. Am J Obstet Gynecol. 2009;200:419.e1–7. Wright JD, Fiorelli J, Kansler AL, et al. Optimizing the management of stage II endometrial cancer: the role of radical hysterectomy and radiation. Am J Obstet Gynecol. 2009;200:419.e1–7.
11.
Zurück zum Zitat Wojcieszynski AP, Hullett CR, Medlin EE, et al. The role of radiation therapy in the treatment of stage II endometrial cancer: a large database study. Brachytherapy. 2018;17:645–52.CrossRefPubMed Wojcieszynski AP, Hullett CR, Medlin EE, et al. The role of radiation therapy in the treatment of stage II endometrial cancer: a large database study. Brachytherapy. 2018;17:645–52.CrossRefPubMed
12.
Zurück zum Zitat Boffa DJ, Rosen JE, Mallin K, et al. Using the National Cancer Database for outcomes research: a review. JAMA Oncol. 2017;3:1722–8. Boffa DJ, Rosen JE, Mallin K, et al. Using the National Cancer Database for outcomes research: a review. JAMA Oncol. 2017;3:1722–8.
13.
Zurück zum Zitat Ayhan A, Taskiran C, Celik C, Yuce K. The long-term survival of women with surgical stage II endometrioid type endometrial cancer. Gynecol Oncol. 2004;93:9–13.CrossRefPubMed Ayhan A, Taskiran C, Celik C, Yuce K. The long-term survival of women with surgical stage II endometrioid type endometrial cancer. Gynecol Oncol. 2004;93:9–13.CrossRefPubMed
14.
Zurück zum Zitat Boente MP, Yordan EJ, McIntosh DG, et al. Prognostic factors and long-term survival in endometrial adenocarcinoma with cervical involvement. Gynecol Oncol. 1993;51:316–22.CrossRefPubMed Boente MP, Yordan EJ, McIntosh DG, et al. Prognostic factors and long-term survival in endometrial adenocarcinoma with cervical involvement. Gynecol Oncol. 1993;51:316–22.CrossRefPubMed
15.
Zurück zum Zitat Cohn DE, Woeste EM, Cacchio S, et al. Clinical and pathologic correlates in surgical stage II endometrial carcinoma. Obstet Gynecol. 2007;109:1062–7.CrossRefPubMed Cohn DE, Woeste EM, Cacchio S, et al. Clinical and pathologic correlates in surgical stage II endometrial carcinoma. Obstet Gynecol. 2007;109:1062–7.CrossRefPubMed
16.
Zurück zum Zitat Cornelison TL, Trimble EL, Kosary CL. SEER data, corpus uteri cancer: treatment trends versus survival for FIGO Stage II, 1988–1994. Gynecol Oncol. 1999;74:350–5.CrossRefPubMed Cornelison TL, Trimble EL, Kosary CL. SEER data, corpus uteri cancer: treatment trends versus survival for FIGO Stage II, 1988–1994. Gynecol Oncol. 1999;74:350–5.CrossRefPubMed
17.
Zurück zum Zitat Fu HC, Chen JR, Chen MY, et al. Treatment outcomes of patients with stage II pure endometrioid-type endometrial cancer: a Taiwanese Gynecologic Oncology Group (TGOG-2006) retrospective cohort study. J Gynecol Oncol. 2018;29:e76.CrossRefPubMedPubMedCentral Fu HC, Chen JR, Chen MY, et al. Treatment outcomes of patients with stage II pure endometrioid-type endometrial cancer: a Taiwanese Gynecologic Oncology Group (TGOG-2006) retrospective cohort study. J Gynecol Oncol. 2018;29:e76.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Leminen A, Forss M, Lehtovirta P. Endometrial adenocarcinoma with clinical evidence of cervical involvement: accuracy of diagnostic procedures, clinical course, and prognostic factors. Acta Obstet Gynecol Scand. 1995;74:61–6.CrossRefPubMed Leminen A, Forss M, Lehtovirta P. Endometrial adenocarcinoma with clinical evidence of cervical involvement: accuracy of diagnostic procedures, clinical course, and prognostic factors. Acta Obstet Gynecol Scand. 1995;74:61–6.CrossRefPubMed
19.
Zurück zum Zitat Orezzoli JP, Sioletic S, Olawaiye A, Oliva E, Del CM. Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion. Gynecol Oncol. 2009;113:316–23.CrossRefPubMed Orezzoli JP, Sioletic S, Olawaiye A, Oliva E, Del CM. Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion. Gynecol Oncol. 2009;113:316–23.CrossRefPubMed
20.
Zurück zum Zitat Phelippeau J, Koskas M. Impact of radical hysterectomy on survival in patients with stage 2 type 1 endometrial carcinoma: a matched cohort study. Ann Surg Oncol. 2016;23:4361–7.CrossRefPubMed Phelippeau J, Koskas M. Impact of radical hysterectomy on survival in patients with stage 2 type 1 endometrial carcinoma: a matched cohort study. Ann Surg Oncol. 2016;23:4361–7.CrossRefPubMed
21.
Zurück zum Zitat Sartori E, Gadducci A, Landoni F, et al. Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy. Int J Gynecol Cancer. 2001;11:430–7.CrossRefPubMed Sartori E, Gadducci A, Landoni F, et al. Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy. Int J Gynecol Cancer. 2001;11:430–7.CrossRefPubMed
22.
Zurück zum Zitat Takano M, Ochi H, Takei Y, et al. Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)? Br J Cancer. 2013;109:1760–5.CrossRefPubMedPubMedCentral Takano M, Ochi H, Takei Y, et al. Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)? Br J Cancer. 2013;109:1760–5.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Parsons L, Cesare F. Wertheim hysterectomy in the treatment of endometrial carcinoma. Surg Gynecol Obstet. 1959;108:582–90.PubMed Parsons L, Cesare F. Wertheim hysterectomy in the treatment of endometrial carcinoma. Surg Gynecol Obstet. 1959;108:582–90.PubMed
24.
Zurück zum Zitat Lefevre H. Node dissection in cancer of the endometrium. Surg Gynecol Obstet. 1956;102:649.PubMed Lefevre H. Node dissection in cancer of the endometrium. Surg Gynecol Obstet. 1956;102:649.PubMed
25.
Zurück zum Zitat Roberts DW. Carcinoma of the body of the uterus at Chelsea Hospital for Women, 1943–1953. J Obstet Gynaecol Br Emp. 1961;68:132–8.CrossRefPubMed Roberts DW. Carcinoma of the body of the uterus at Chelsea Hospital for Women, 1943–1953. J Obstet Gynaecol Br Emp. 1961;68:132–8.CrossRefPubMed
26.
Zurück zum Zitat Boente MP, Orandi YA, Yordan EL, et al. Recurrence patterns and complications in endometrial adenocarcinoma with cervical involvement. Ann Surg Oncol. 1995;2:138–44.CrossRefPubMed Boente MP, Orandi YA, Yordan EL, et al. Recurrence patterns and complications in endometrial adenocarcinoma with cervical involvement. Ann Surg Oncol. 1995;2:138–44.CrossRefPubMed
27.
Zurück zum Zitat Signorelli M, Lissoni AA, Cormio G, et al. Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study. Ann Surg Oncol. 2009;16:3431–41.CrossRefPubMed Signorelli M, Lissoni AA, Cormio G, et al. Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study. Ann Surg Oncol. 2009;16:3431–41.CrossRefPubMed
28.
Zurück zum Zitat Macdonald MC, Tidy JA. Can we be less radical with surgery for early cervical cancer? Curr Oncol Rep. 2016;18:16.CrossRefPubMed Macdonald MC, Tidy JA. Can we be less radical with surgery for early cervical cancer? Curr Oncol Rep. 2016;18:16.CrossRefPubMed
29.
Zurück zum Zitat ASTEC/EN.5 Study Group, Blake P, Swart AM, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009;373:137–46. ASTEC/EN.5 Study Group, Blake P, Swart AM, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009;373:137–46.
30.
Zurück zum Zitat Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol. 2008;108:226–33.CrossRefPubMed Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol. 2008;108:226–33.CrossRefPubMed
31.
Zurück zum Zitat Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744–51.CrossRefPubMed Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744–51.CrossRefPubMed
32.
Zurück zum Zitat Creutzberg CL, Nout RA, Lybeert MLM, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2011;81:e631–8.CrossRefPubMed Creutzberg CL, Nout RA, Lybeert MLM, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2011;81:e631–8.CrossRefPubMed
33.
Zurück zum Zitat Alektiar KM, Venkatraman E, Chi DS, Barakat RR. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int J Radiat Oncol Biol Phys. 2005;62:111–7.CrossRefPubMed Alektiar KM, Venkatraman E, Chi DS, Barakat RR. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int J Radiat Oncol Biol Phys. 2005;62:111–7.CrossRefPubMed
34.
Zurück zum Zitat Nout RA, Smit V, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375:816–23.CrossRefPubMed Nout RA, Smit V, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375:816–23.CrossRefPubMed
35.
Zurück zum Zitat Shisler R, Sinnott JA, Wang V, et al. Life after endometrial cancer: a systematic review of patient-reported outcomes. Gynecol Oncol. 2018;148:403–13.CrossRefPubMed Shisler R, Sinnott JA, Wang V, et al. Life after endometrial cancer: a systematic review of patient-reported outcomes. Gynecol Oncol. 2018;148:403–13.CrossRefPubMed
36.
Zurück zum Zitat Damast S, Alektiar K, Eaton A, et al. Comparative patient-centered outcomes (health state and adverse sexual symptoms) between adjuvant brachytherapy versus no adjuvant brachytherapy in early-stage endometrial cancer. Ann Surg Oncol. 2014;21:2740–54.CrossRefPubMed Damast S, Alektiar K, Eaton A, et al. Comparative patient-centered outcomes (health state and adverse sexual symptoms) between adjuvant brachytherapy versus no adjuvant brachytherapy in early-stage endometrial cancer. Ann Surg Oncol. 2014;21:2740–54.CrossRefPubMed
37.
Zurück zum Zitat Becker M, Malafy T, Bossart M, et al. Quality of life and sexual functioning in endometrial cancer survivors. Gynecol Oncol. 2011;121:169–73.CrossRefPubMed Becker M, Malafy T, Bossart M, et al. Quality of life and sexual functioning in endometrial cancer survivors. Gynecol Oncol. 2011;121:169–73.CrossRefPubMed
38.
Zurück zum Zitat Quick AM, Seamon LG, Abdel-Rasoul M, Salani R, Martin D. Sexual function after intracavitary vaginal brachytherapy for early-stage endometrial carcinoma. Int J Gynecol Cancer. 2012;22:703–8.CrossRefPubMedPubMedCentral Quick AM, Seamon LG, Abdel-Rasoul M, Salani R, Martin D. Sexual function after intracavitary vaginal brachytherapy for early-stage endometrial carcinoma. Int J Gynecol Cancer. 2012;22:703–8.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. New Engl J Med. 2018;379:1895–904.CrossRefPubMed Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. New Engl J Med. 2018;379:1895–904.CrossRefPubMed
40.
Zurück zum Zitat Walker JL, Piedmonte MR, Spirtos NM, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol. 2012;30:695–700.CrossRefPubMedPubMedCentral Walker JL, Piedmonte MR, Spirtos NM, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol. 2012;30:695–700.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Janda M, Gebski V, Davies LC, et al. Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer: a randomized clinical trial. JAMA. 2017;317:1224–33.CrossRefPubMed Janda M, Gebski V, Davies LC, et al. Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer: a randomized clinical trial. JAMA. 2017;317:1224–33.CrossRefPubMed
42.
Zurück zum Zitat Galaal K, Donkers H, Bryant A, Lopes AD. Laparoscopy versus laparotomy for the management of early-stage endometrial cancer. Cochrane Database Syst Rev. 2018;10:CD006655.PubMed Galaal K, Donkers H, Bryant A, Lopes AD. Laparoscopy versus laparotomy for the management of early-stage endometrial cancer. Cochrane Database Syst Rev. 2018;10:CD006655.PubMed
43.
Zurück zum Zitat Rutledge F. The role of radical hysterectomy in adenocarcinoma of the endometrium. Gynecol Oncol. 1974;2:331.CrossRefPubMed Rutledge F. The role of radical hysterectomy in adenocarcinoma of the endometrium. Gynecol Oncol. 1974;2:331.CrossRefPubMed
44.
Zurück zum Zitat Yura Y, Yura S, Tauchi K, et al. Parametrial involvement in endometrial carcinomas: its incidence and correlation with other histological parameters. Gynecol. Oncol. 1996;63:114–9. Yura Y, Yura S, Tauchi K, et al. Parametrial involvement in endometrial carcinomas: its incidence and correlation with other histological parameters. Gynecol. Oncol. 1996;63:114–9.
45.
Zurück zum Zitat Watanabe Y, Satou T, Nakai H, et al. Evaluation of parametrial spread in endometrial carcinoma. Obstet Gynecol. 2010;116:1027–34.CrossRefPubMed Watanabe Y, Satou T, Nakai H, et al. Evaluation of parametrial spread in endometrial carcinoma. Obstet Gynecol. 2010;116:1027–34.CrossRefPubMed
46.
Zurück zum Zitat Danoff BF, McDay J, Louka M, et al. Stage III endometrial carcinoma: analysis of patterns of failure and therapeutic implications. Int J Radiat Oncol Biol Phys. 1980;6:1491–5.CrossRefPubMed Danoff BF, McDay J, Louka M, et al. Stage III endometrial carcinoma: analysis of patterns of failure and therapeutic implications. Int J Radiat Oncol Biol Phys. 1980;6:1491–5.CrossRefPubMed
47.
Zurück zum Zitat Behbakht K, Yordan EL, Casey C, et al. Prognostic indicators of survival in advanced endometrial cancer. Gynecol Oncol. 1994;55(3 Pt 1):363.CrossRefPubMed Behbakht K, Yordan EL, Casey C, et al. Prognostic indicators of survival in advanced endometrial cancer. Gynecol Oncol. 1994;55(3 Pt 1):363.CrossRefPubMed
Metadaten
Titel
Impact of Radical Hysterectomy Versus Simple Hysterectomy on Survival of Patients with Stage 2 Endometrial Cancer: A Meta-analysis
verfasst von
Ting Liu, MD
Hua Tu, MD
Yongxue Li, MD
Zhimin Liu, MD
Guochen Liu, MD
Haifeng Gu, MD
Publikationsdatum
30.05.2019
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 9/2019
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07472-y

Weitere Artikel der Ausgabe 9/2019

Annals of Surgical Oncology 9/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.